Differences in nocturnal basal and rhythmic prolactin secretion in untreated compared to treated HIV-infected men are associated with CD4+ T-lymphocytes

Immunology and Cell Biology

Volumn 82, Issue 1, 2004, Pages 24-31

  Parra, Adalberto ^a   Reyes Terán, Gustavo ^b   Ramírez Peredo, Jorge ^a   Jacquemin, Benedicte ^b   Quiroz, Verónica ^b   Cárdenas, María ^c   García Sancho, María Cecilia ^b   Larrea, Fernando ^c  

^a INSTITUTO NACIONAL DE PERINATOLOGÍA   (Mexico)

^b INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^c INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

AIDS; CD4+ T cells; Dopaminergic tone; Highly active antiretroviral treatment; HIV infection; Men; Nocturnal rhythmic prolactin secretion

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; EFAVIRENZ; INDINAVIR; LAMIVUDINE; PROLACTIN; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHALAMUS; LYMPHOCYTE COUNT; MALE; NUCLEIC ACID SEQUENCE BASED AMPLIFICATION; PROLACTIN RELEASE; PULSATILE HORMONE RELEASE; T LYMPHOCYTE; VIRUS LOAD; VOLUNTEER;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CIRCADIAN RHYTHM; CROSS-SECTIONAL STUDIES; DARKNESS; HIV; HIV INFECTIONS; HUMANS; MALE; PROLACTIN; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 1642390697     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1711.2004.01201.x     Document Type: Article

References (48)

1. Ben-Jonathan N. Dopamine: a prolactin-inhibiting hormone. Endocr. Rev. 1985; 6: 564-89.
2. Sassin JF, Frantz AG, Witzman ED, Kapen S. Human prolactin: 24-hr pattern with increased release during sleep. Science 1972; 177: 1205-7.
3. Veldhuis JD, Iranmanesh A, Johnson ML, Lizarralde G. Twenty-four hour rhythms in plasma concentrations of adenohypophyseal hormones are generated by distinct amplitude and/or frequency modulation of underlying pituitary secretory bursts. J. Clin. Endocrinol. Metab 1990; 71: 1616-23.
4. Iranmanesh A, Mulligan T, Veldhuis JD. Mechanisms subserving the physiological nocturnal relative hypoprolactinemia of healthy older men: Dual decline in prolactin secretory burst mass and basal release with preservation of pulse duration, frequency, and interpulse interval - a General Clinical Research Center study. J. Clin. Endocrinol. Metab 1999; 84: 1083-90.
5. Tollis G, Franks S. Physiology and pathology of prolactin secretion. In: Tollis, G Labrie, F Martin, JB (eds). Clinical Endocrinology: a Pathopysiological Approach. New York: Raven Press, 1979; 291-317.
6. Veldhuis JD, Johnson ML. Operating characteristics of the human male hypothalamo-pituitary-gonadal axis, circadian, ultradian and pulsatile release of prolactin, and its temporal coupling with luteinizing hormone. J. Clin. Endocrinol. Metab. 1988; 67: 116-23.
7. Begot M, Hemming FJ, Dubois PM, Combarnous Y, Aubert ML. Induction of pituitary lactotrope differentiation by luteinizing hormone a subunit. Science 1984; 226: 566-8.
8. Keenan D, Veldhuis JD. Stochastic model of admixed basal and pulsatile hormone secretion as modulated by a deterministic oscillator. Am. J. Physiol. 1997; 273: R1182-92.
9. Grinspoon SK, Bilezikian JP. HIV disease and the endocrine system. N. Engl. J. Med. 1992; 327: 1360-5.
10. Sellmeyer DE, Grunfeld C. Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome. Endocr. Rev. 1996; 17: 518-32.
11. Matera L. Endocrine, paracrine and autocrine actions of prolactin on immune cells. Life Sci. 1996; 59: 599-614.
12. Yu-Lee L. Molecular actions of prolactin in the immune system. Proc. Soc. Exp. Biol. Medical 1997; 215: 35-52.
13. Clevenger CV, Freier DO, Kline JB. Prolactin receptor signal transduction in cells of the immune system. J. Endocrinol. 1998; 157: 187-97.
14. Clevenger CV, Sillman AL, Hanley-Hyde J, Pristowsky MB. Requirement for prolactin during cell cycle regulated gene expression in cloned T-lymphocytes. Endocrinology 1992; 130: 3216-22.
15. Pellegrini I, Lebrun JJ, Ali S, Kelly PA, Gagnerault MC. Expression of prolactin and its receptor in human lymphoid cells. Mol. Endocrinol. 1992; 6: 1023-31.
16. Parra A, Ramirez-Peredo J, Coutiño B et al. Impaired metoclopramide-induced pituitary prolactin release in men with human immunodeficiency virus infection. J. Laboratory Clin. Med. 1999; 133: 70-4.
17. Parra A, Ramírez-Peredo J, Larrea F et al. Decreased endogenous dopaminergic tone and increased basal bioactive prolactin in men with human immunodeficiency virus infection. Clin. Endocrinol. (Oxf) 2001; 54: 731-8.
18. Parra A, Ramírez-Peredo J, Larrea F et al. Serum prolactin is associated with apoptosis in men with human immunodeficiency virus infection. Immunol. Cell Biol. 2001; 79: 285-90.
19. Richards SM, Garman RD, Reyes L, Kavanagh B, McPherson JM. Prolactin is an antagonist of TGF-β activity and promotes proliferation of murine B cell hybridomas. Cell. Immunol. 1998; 184: 85-91.
20. Parra A, Ramírez-Peredo J. The uncoupled couple? Prolactin and CD4 lymphocytes in HIV infection. Med. Hypotheses 1999; 53: 425-8.
21. Centers for Disease Control and Prevention 1992-1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbid. Mortal. Week Rep. 41: (No RR-17) 1-19.
22. Larrea F, Sandoval JL, Salinas E, Franco-Rodriguez VA, Méndez I, Ulloa-Aguirre A. Evidence of an altered luteinizing hormone sensitivity to naloxone in pathological hyperprolactinemia. Clin. Endocrinol. (Oxf.) 1995; 43: 591-600.
23. Johnson ML, Veldhuis JD. Evolution of deconvolution analysis as a hormone pulse detection method. Meth. Neurosci. 1995; 28: 1-24.
24. Veldhuis JD, Moorman J, Johnson ML. Deconvolution analysis of neuroendocrine data: waveform-independent methods and applications. Meth. Neurosci. 1994; 20: 279-325.
25. Sievertsen GD, Lim VS, Nakawatase C, Frohman LA. Metabolic clearance and secretion rates of human prolactin in normal subjects and in patients with chronic renal failure. J. Clin. Endocrinol. Metab 1980; 50: 846-52.
26. Groote Veldman R, Frölich M, Pincus SM, Veldhuis JD, Roelfsema F. Basal, pulsatile, entropic, and 24-hour rhythmic features of secondary hyperprolactinemia due to functional pituitary stalk disconnection mimic tumoral (primary) hyperprolactinemia. J. Clin. Endocrinol. Metab 2001; 86: 1562-7.
27. Pincus SM. Approximate entropy as a measure of system complexity. Proc. Natl Acad. Sci. USA 1991; 88; 2297-301.
28. Pincus S, Singer B. Randomness and degrees of irregularity. Proc. Natl. Acad. Sci. USA 1996; 93: 2083-8.
29. Sassin JF, Frantz AG, Kapen S, Weitzman ED. The nocturnal rise of human prolactin is dependent on sleep. J. Clin. Endocrinol. Metab. 1973; 37: 436-40.
30. Logue FC, Fraser WD, O'Reilly DSJ et al. Sleep shift dissociates the nocturnal peaks of parathyroid hormone (1-84), nephrogenous cyclic adenosine monophosphate, and prolactin in men. J. Clin. Endocrinol. Metab. 1992; 75: 25-9.
31. Norman SE, Chediak AD, et al. Sleep disturbances in men with asymptomatic human immunodeficiency (HIV) infection. Sleep 1992; 15: 150-5.
32. Darko DF, Miller JC, Gallen C et al. Sleep electroencephalogram delta-frequency amplitude, night plasma levels of tumor necrosis factor-α, and human immunodeficiency virus infection. Proc. Natl Acad. Sci. USA 1995; 92: 12080-4.
33. Waldstreicher J, Duffy JF, Brown EN, Rogacz S, Allan JS, Czeisler CA. Gender differences in the temporal organization of prolactin (PRL) secretion: Evidence for a sleep-independent circadian rhythm of circulating PRL levels - A clinical research center study. J. Clin. Endocrinol. Metab. 1996; 81: 1483-7.
34. Berger JR, Levy JA. The human immunodeficiency virus, type 1: The virus and its role in neurologic disease. Semin. Neurol. 1992; 12: 1-9.
35. Bennett BA, Rusyniak DE, Hollingsworth CK. HIV-1 gp 120-induced neurotoxicity to midbrain dopamine cultures. Brain Res. 1995; 705: 169-76.
36. Van den Berghe G, Veldhuis JD, de Zegher F, Wouters P, Bowers CY, Bouillon R. Growth hormone-releasing peptide-2 infusion synchronizes growth hormone, thyrotropin and prolactin release in prolonged critical illness. Eur. J. Endocrinol 1999; 140: 17-22.
37. Veldhuis JD, Pincus SM. Orderliness of hormone release patterns: a complementary measure to conventional pulsatile and circadian analyses. Eur. J. Endocrinol. 1998; 138: 358-62.
38. Dorshkind K, Horseman ND. The roles of prolactin, growth hormone, insulin-like growth factor-I, and thyroid hormones in lymphocyte development and function: Insights from genetic models of hormone and hormone receptor deficiency. Endocr. Rev. 2000; 21: 292-312.
39. Gala RR. The physiology and mechanisms of the stress-induced changes in prolactin secretion in the rat. Life Sci. 1990; 46: 1407-20.
40. Kant GJ, Bauman RA, Anderson SM, Mougey EH. Effects of controllable vs uncontrollable chronic stress on stress-responsive plasma hormones. Physiol. Behav. 1992; 51: 1285-8.
41. Weimann E, Baixeras E, Zamzani N, Kelly P. Prolactin blocks glucocorticoid induced cell death by inhibiting the disruption of the mitochondrial membrane. Leuk. Res. 1999; 23: 751-62.
42. Matera L. Action of pituitary and lymphocyte prolactin. Neuroimmunomodulation 1997; 4: 171-80.
43. Gerli R, Rambotti P, Nicolette J, Orlandi S, Migliorate G, Riccardi C. Reduced number of natural killer cells in patients with pathological hyperprolactinemia. Clin. Exp. Immunol. 1986; 64: 399-406.
44. Clevenger CV, Rusell DA, Appasamy PM, Prystowsky MB. Regulation of interleukin-2-driven T-lymphocyte proliferation by prolactin. Proc. Natl Acad. Sci. USA 1990; 87: 6460-4.
45. Matera L, Cesano A, Bellone G, Oberholtzer E. Modulatory effect of prolactin on the resting and mitogen-induced activity of T, B, and NK lymphocytes. Brain Behav. Immun. 1992; 6: 409-17.
46. Blankson JN, Persaud D, Siliciano RF. The challenge of viral reservoirs in HIV-1 infection. Annu. Rev. Med. 2002; 53: 557-93.
47. Richards SM, Murphy WJ. Use of human prolactin as a therapeutic protein to potentiate immunohematopoietic function. J. Neuroimmunol. 2000; 109: 56-62.
48. Matera L, Mon M, Geuna M, Buttiglieri S, Palestro G. Prolactin in autoimmunity and antitumor defence. J. Neuroimmunol. 2000; 109: 47-55.